

WEDNESDAY 15th JULY 2015 COMMENCING 09.30 AM
AT [CARDIFF METROPOLITAN UNIVERSITY](#), LLANDAFF
CAMPUS, WESTERN AVENUE, CARDIFF CF5 2YB

AGENDA

- | | Enclosure |
|--|----------------------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0715 |
| 5. Chairman's report (verbal update) | |
| 6. Appraisal 1: Full Submission
Brimonidine (Mirvaso[®]) for the symptomatic treatment of facial erythema of rosacea in adult patients | 2/AWMSG/0715
Appendices |
| 7. Appraisal 2: Full Submission
Darunavir/cobicistat (Rezolsta[®]) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years or older | 3/AWMSG/0715
Appendices |
| 8. Appraisal 3: Limited Submission
Magnesium aspartate dihydrate (Magnaspartate[®]) for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years | 4/AWMSG/0715
Appendices |
| 9. Appraisal 4: Limited Submission
Tacrolimus (Envarsus[®]) for prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients | 5/AWMSG/0715
Appendices |
| 10. All Wales Prescribing Advisory Group – Feedback from meeting held 3rd June 2015 | 6/AWMSG/0715 |

To protect commercial confidentiality the following appraisals will be held in private

- | | |
|--|----------------------------|
| 11. Reappraisal following Independent Review
Pomalidomide (Imnovid®) in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy | 7/AWMSG/0715
Appendices |
| 12. Reappraisal following Independent Review
Enzalutamide (Xtandi®) for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated | 8/AWMSG/0715
Appendices |

The meeting will open to the public for the announcement of the recommendation

Date of next meeting: 16th September 2015 in Cardiff